Pyxis Oncology, Inc. Common Stock (PYXS) is a publicly traded Healthcare sector company. As of July 11, 2026, PYXS trades at $2.69 with a market cap of $167.26M and a P/E ratio of -1.97. PYXS moved +1.52% today. Year to date, PYXS is +132.17%; over the trailing twelve months it is +124.37%. Its 52-week range spans $0.83 to $5.55. Analyst consensus is strong buy with an average price target of $6.50. Rallies surfaces PYXS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for PYXS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $2.69 |
| Market Cap | $167.26M |
| P/E Ratio | -1.97 |
| EPS | $-1.31 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.55 |
| 52-Week Low | $0.83 |
| Volume | 809.49K |
| Avg Volume | 0 |
| Revenue (TTM) | $13.86M |
| Net Income | $-81.73M |
| Gross Margin | 0.00% |
7 analysts cover PYXS: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.50.